Breast Tumor Board Case Presentations (November 18, 2024)
This Breast Tumor Board session will take place on Monday, November 18, 2024 at 7:00 a.m. This series is restricted to tumor board participants and will not be broadcast.
Activity Information
Needs Statement
Medical oncologists, surgical oncologists, plastic surgeons, pathologists, radiologists, radiation oncologists, internists, general surgeons, and genetic counselors need to receive regular updates on the continually evolving advances in breast cancer management. The tumor board aims to increase the knowledge of learners by using a multidisciplinary case approach and follow-up recommendations to enhance the quality of breast cancer care and to improve patient outcomes.
Educational Objectives
At the conclusion of the sessions, the participants should be able to:
- Discuss how the roles of surgery and radiation have evolved in the local management of breast cancer.
- Utilize FDA-approved chemotherapy, targeted therapy, and immunotherapy to treat various types of breast cancer.
- Recognize the indications for germline and somatic genetic testing and incorporate the results into breast cancer management.
- Distinguish the roles of various types of breast cancer imaging in the diagnosis and management of breast cancer.
Target Audience
Professional Categories
- Physicians
- Fellows
- Residents
- Other Health Professionals
Specialties
- Breast Surgery
- Oncology
- Pathology
- Radiology
- Surgical Oncology
Interest Groups
- Hospital Medicine
Accreditation/Credit Designation
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Activity Directors
Disclosure Policy
Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.
In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.
In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.
BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Presenters
-
Ahmed Elkhanany, M.D.
Assistant Professor of Breast Oncology
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Brian K. Lassinger, M.S.
Assistant Professor of Surgery, PA-C
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Michelle S Ludwig, MD, MPH, PhD
Associate Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Julie Rani Nangia, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Eric J. Silberfein, M.D.
Associate Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Activity Directors
-
Julie Rani Nangia, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Eric J. Silberfein, M.D.
Associate Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Planning Committee Members
-
Ahmed Elkhanany, M.D.
Assistant Professor of Breast Oncology
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Valentina Hoyos, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
- Consultancy: AstraZeneca
-
Brian K. Lassinger, M.S.
Assistant Professor of Surgery, PA-C
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Michelle S Ludwig, MD, MPH, PhD
Associate Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Chandandeep Nagi, M.D.
Associate Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Julie Rani Nangia, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Karla Sepulveda, M.D.
Associate Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
-
Eric J. Silberfein, M.D.
Associate Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Cathy M. Sullivan, M.S., B.S., C.G.C.
Instructor, Oncology Genetic Counseling
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Nataly Torrejon, M.D.
Hematology and Oncology Fellow
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Health Topics
Presenters: